Literature DB >> 33668389

Ultrasound-Assisted Synthesis of 4-Alkoxy-2-methylquinolines: An Efficient Method toward Antitubercular Drug Candidates.

Ana Flávia Borsoi1,2, Josiane Delgado Paz1,3, Kenia Pissinate1, Raoní Scheibler Rambo1, Víctor Zajaczkowski Pestana1, Cristiano Valim Bizarro1,3, Luiz Augusto Basso1,2,3, Pablo Machado1,2,3.   

Abstract

Tuberculosis (TB) has been described as a global health crisis since the second half of the 1990s. Mycobacterium tuberculosis (Mtb), the etiologic agent of TB in humans, is a very successful pathogen, being the main cause of death in the population among infectious agents. In 2019, it was estimated that around 10 million individuals were contaminated by this bacillus and about 1.2 million succumbed to the disease. In recent years, our research group has reported the design and synthesis of quinoline derivatives as drug candidates for the treatment of TB. These compounds have demonstrated potent and selective growth inhibition of drug-susceptible and drug-resistant Mtb strains. Herein, a new synthetic approach was established providing efficient and rapid access (15 min) to a series of 4-alkoxy-6-methoxy-2-methylquinolines using ultrasound energy. The new synthetic protocol provides a simple procedure utilizing an open vessel system that affords the target products at satisfactory yields (45-84%) and elevated purities (≥95%). The methodology allows the evaluation of a larger number of molecules in assays against the bacillus, facilitating the determination of the structure-activity relationship with a reduced environmental cost.

Entities:  

Keywords:  antituberculosis drug discovery; heterocyclic synthesis; new methods; sonochemistry

Mesh:

Substances:

Year:  2021        PMID: 33668389      PMCID: PMC7956363          DOI: 10.3390/molecules26051215

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.411


  14 in total

Review 1.  Power ultrasound in organic synthesis: moving cavitational chemistry from academia to innovative and large-scale applications.

Authors:  Giancarlo Cravotto; Pedro Cintas
Journal:  Chem Soc Rev       Date:  2005-10-10       Impact factor: 54.564

2.  Solvent-free heterocyclic synthesis.

Authors:  Marcos A P Martins; Clarissa P Frizzo; Dayse N Moreira; Lilian Buriol; Pablo Machado
Journal:  Chem Rev       Date:  2009-09       Impact factor: 60.622

Review 3.  Recent developments on ultrasound assisted catalyst-free organic synthesis.

Authors:  Bubun Banerjee
Journal:  Ultrason Sonochem       Date:  2016-09-28       Impact factor: 7.491

Review 4.  Sustainable practices in medicinal chemistry: current state and future directions.

Authors:  Marian C Bryan; Barry Dillon; Lawrence G Hamann; Gregory J Hughes; Michael E Kopach; Emily A Peterson; Mehrnaz Pourashraf; Izzat Raheem; Paul Richardson; Daniel Richter; Helen F Sneddon
Journal:  J Med Chem       Date:  2013-05-09       Impact factor: 7.446

5.  4-Substituted thioquinolines and thiazoloquinolines: potent, selective, and Tween-80 in vitro dependent families of antitubercular agents with moderate in vivo activity.

Authors:  Jaime Escribano; Cristina Rivero-Hernández; Hilda Rivera; David Barros; Julia Castro-Pichel; Esther Pérez-Herrán; Alfonso Mendoza-Losana; Iñigo Angulo-Barturen; Santiago Ferrer-Bazaga; Elena Jiménez-Navarro; Lluís Ballell
Journal:  ChemMedChem       Date:  2011-09-16       Impact factor: 3.466

6.  2-(Quinolin-4-yloxy)acetamides Are Active against Drug-Susceptible and Drug-Resistant Mycobacterium tuberculosis Strains.

Authors:  Kenia Pissinate; Anne Drumond Villela; Valnês Rodrigues-Junior; Bruno Couto Giacobbo; Estêvão Silveira Grams; Bruno Lopes Abbadi; Rogério Valim Trindade; Laura Roesler Nery; Carla Denise Bonan; Davi Fernando Back; Maria Martha Campos; Luiz Augusto Basso; Diógenes Santiago Santos; Pablo Machado
Journal:  ACS Med Chem Lett       Date:  2016-01-11       Impact factor: 4.345

7.  New insights into the SAR and drug combination synergy of 2-(quinolin-4-yloxy)acetamides against Mycobacterium tuberculosis.

Authors:  Bruno Couto Giacobbo; Kenia Pissinate; Valnês Rodrigues-Junior; Anne Drumond Villela; Estêvão Silveira Grams; Bruno Lopes Abbadi; Fernanda Teixeira Subtil; Nathalia Sperotto; Rogério Valim Trindade; Davi Fernando Back; Maria Martha Campos; Luiz Augusto Basso; Pablo Machado; Diógenes Santiago Santos
Journal:  Eur J Med Chem       Date:  2016-11-23       Impact factor: 6.514

8.  Delamanid for multidrug-resistant pulmonary tuberculosis.

Authors:  Maria Tarcela Gler; Vija Skripconoka; Epifanio Sanchez-Garavito; Heping Xiao; Jose L Cabrera-Rivero; Dante E Vargas-Vasquez; Mengqiu Gao; Mohamed Awad; Seung-Kyu Park; Tae Sun Shim; Gee Young Suh; Manfred Danilovits; Hideo Ogata; Anu Kurve; Joon Chang; Katsuhiro Suzuki; Thelma Tupasi; Won-Jung Koh; Barbara Seaworth; Lawrence J Geiter; Charles D Wells
Journal:  N Engl J Med       Date:  2012-06-07       Impact factor: 91.245

9.  Design, synthesis, and evaluation of new 2-(quinoline-4-yloxy)acetamide-based antituberculosis agents.

Authors:  Ana Flávia Borsoi; Josiane Delgado Paz; Bruno Lopes Abbadi; Fernanda Souza Macchi; Nathalia Sperotto; Kenia Pissinate; Raoní S Rambo; Alessandro Silva Ramos; Diana Machado; Miguel Viveiros; Cristiano Valim Bizarro; Luiz Augusto Basso; Pablo Machado
Journal:  Eur J Med Chem       Date:  2020-02-21       Impact factor: 6.514

10.  Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis.

Authors:  Guido V Bloemberg; Peter M Keller; David Stucki; David Stuckia; Andrej Trauner; Sonia Borrell; Tsogyal Latshang; Mireia Coscolla; Thomas Rothe; Rico Hömke; Claudia Ritter; Julia Feldmann; Bettina Schulthess; Sebastien Gagneux; Erik C Böttger
Journal:  N Engl J Med       Date:  2015-11-12       Impact factor: 91.245

View more
  1 in total

1.  Ultrasound-Assisted Synthesis of Fluorescent Azatetracyclic Derivatives: An Energy-Efficient Approach.

Authors:  Gheorghita Zbancioc; Catalina-Ionica Ciobanu; Ionel I Mangalagiu; Costel Moldoveanu
Journal:  Molecules       Date:  2022-05-16       Impact factor: 4.927

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.